Long‐term efficacy and safety of once‐monthly pasireotide in Cushing's disease: A Phase III extension study

OBJECTIVES: Many patients with Cushing's disease (CD) require chronic pharmacotherapy to control their hypercortisolism. We evaluated the efficacy and safety of long‐acting pasireotide during a long‐term extension study in patients with CD. DESIGN: Open‐label extension to a 12‐month Phase III s...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleseriu, Maria, Petersenn, Stephan, Biller, Beverly M. K., Kadioglu, Pinar, De Block, Christophe, T'Sjoen, Guy, Vantyghem, Marie‐Christine, Tauchmanova, Libuse, Wojna, Judi, Roughton, Michael, Lacroix, André, Newell‐Price, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899900/
https://www.ncbi.nlm.nih.gov/pubmed/31465533
http://dx.doi.org/10.1111/cen.14081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899900/
https://www.ncbi.nlm.nih.gov/pubmed/31465533
http://dx.doi.org/10.1111/cen.14081

Ejemplares similares